This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Idera Pharmaceuticals Announces Results Of Phase 1 Clinical Trial Of IMO-8400, Toll-like Receptor Antagonist Drug Candidate For Autoimmune And Inflammatory Diseases

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced results of a Phase 1 clinical trial of IMO-8400, a first-in-class antagonist of Toll-like Receptors (TLRs) 7, 8, and 9 being developed for potential applications in autoimmune and inflammatory diseases. In this trial, IMO-8400 was administered at single escalating dose levels and multiple dose levels weekly for four weeks in healthy subjects. IMO-8400 was well tolerated at all dose levels. IMO-8400-treated subjects showed inhibition of TLR 7-, 8-, and 9-mediated cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), interferon-alpha (IFN-α), and other pro-inflammatory cytokines. These results were presented at the 13th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS), held on June 27-30, 2013, in Boston, MA.

"We are very pleased with the safety and tolerability of IMO-8400 in this trial. Further, IMO-8400 showed strong and sustained inhibition of TLR7-, 8-, and 9- mediated cytokine induction," said Robert D. Arbeit, M.D., Vice President of Clinical Development. "Based on these encouraging results, we have initiated a randomized, double-blind, placebo-controlled Phase 2 trial of IMO-8400 in patients with psoriasis to evaluate PASI score improvement over a 12-week treatment period at three dose levels."

“We anticipate data from the ongoing Phase 2 trial to be available by year-end. Results from this study will inform our decisions regarding later stage clinical development of IMO-8400 in patients with psoriasis and clinical development in other indications,” said Sudhir Agrawal, D.Phil., Chairman and Chief Executive Officer. “IMO-8400 has potential applications in a broad range of autoimmune and inflammatory diseases, in which TLRs 7, 8, and 9 are implicated in exacerbating the disease.”

Phase 1 Clinical Trial Results
  • IMO-8400 was well tolerated in single- and multiple-dose regimens at all dosages
  • The intended pharmacodynamic mechanism of action was demonstrated in IMO-8400 treated subjects
  • Cytokine induction mediated by TLRs 7, 8, and 9 was inhibited in IMO-8400 treated subjects and not in placebo treated subjects
  • The induction of multiple cytokines was inhibited, including TNF-α, IL-1β, IL-6 and IFN-α
  • Inhibition of cytokine induction was sustained for seven days after dosing with IMO-8400
  • Pharmacokinetics showed IMO-8400 was rapidly cleared from plasma with no accumulation
  • Pharmacodynamic results support a weekly dose regimen for evaluation of IMO-8400 in clinical development in autoimmune disease indications

About the IMO-8400 Phase 1 Trial in Healthy Subjects

A Phase 1 clinical trial of IMO-8400 was conducted to assess the safety, pharmacokinetic and pharmacodynamic activity in healthy subjects. This randomized, double-blind, placebo controlled trial enrolled 42 healthy subjects. The single-dose portion of the trial involved three escalating dose levels of 0.1, 0.3 and 0.6 mg/kg of IMO-8400 or placebo, with six subjects receiving each treatment. The multiple-dose portion of this trial involved two dose levels of IMO-8400, 0.3 and 0.6 mg/kg, and placebo, with six subjects receiving each treatment for four weekly doses. Safety and tolerability were monitored throughout the study. Pharmacokinetic activity and pharmacodynamic activity were monitored at specific times.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 0.00%
FB $118.06 0.00%
GOOG $695.70 0.00%
TSLA $222.56 0.00%
YHOO $36.00 0.00%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs